Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Immutep Limited (IMMP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.2300-0.0300 (-1.33%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close2.2600
Open2.2400
Bid2.2300 x 1000
Ask2.3900 x 2900
Day's Range2.2000 - 2.2900
52 Week Range1.8500 - 5.0000
Volume100,535
Avg. Volume103,793
Market Cap197.221M
Beta (5Y Monthly)1.90
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IMMP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Immutep Limited
    Daily – Vickers Top Insider Picks for 07/19/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    24 days agoArgus Research
View more
  • Benzinga

    Immutep's Lung Cancer Candidate Shows Encouraging Efficacy As Second-Line Treatment

    Immutep Limited (NASDAQ: IMMP) announced new interim data from 2nd line non-small cell lung cancer (NSCLC) patients (Part B) in the Phase 2 TACTI-002 trial. Part B evaluates Immutep's lead product candidate, eftilagimod alpha (efti or IMP321), in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in 36 patients. Median overall survival (OS) was 9.7 months for those who received chemo-free therapy of efti in combination with pembrolizumab, comparable with the current standard

  • Simply Wall St.

    Investing in Immutep (ASX:IMM) three years ago would have delivered you a 47% gain

    By buying an index fund, you can roughly match the market return with ease. But if you choose individual stocks with...

  • Benzinga

    Why Are Immutep Shares Trading Higher?

    Immutep Limited (NASDAQ: IMMP) has announced new interim data from the Phase 2 TACTI002 trial of eftilagimod alpha (efti or IMP321), combined with Merck & Co Inc's Keytruda (pembrolizumab). The trial included 36 patients with PD-L1 unselected 2nd line PD-X refractory metastatic non-small cell lung cancer (NSCLC). The patients had advanced disease that progressed after prior standard of care treatment with either anti-PD-(L)1 monotherapy or chemotherapy / anti-PD-(L)1 combo therapy. As of the dat

Advertisement
Advertisement